renal tumors
Post on 05-Jan-2016
50 Views
Preview:
DESCRIPTION
TRANSCRIPT
RENAL TUMORSRENAL TUMORS
DEPARTMENT OF UROLOGY IAŞI – 2013
RENAL TUMORSRENAL TUMORS
benign renal tumors – adenoma, oncocytoma, angiomyolipoma, leiomyoma, lipoma, hemangioma, juxtaglomerular tumors
adenoma – most common, glandular tumors of the renal cortex oncocytoma – large epithelial cells with finely granular
eosinophilic cytoplasm (oncocytes) angiomyolipoma – US & CT are frequently diagnostic (high fat
content), symptoms (bleeding or pain) renal-sparing surgery or renal arterial embolization
RENAL TUMORSRENAL TUMORS
benign renal tumors – adenoma, oncocytoma, angiomyolipoma, leiomyoma, lipoma, hemangioma, juxtaglomerular tumors
ADENOCARCINOMA OF THE KIDNEY(RENAL CELL CARCINOMA - RCC)
2.5% of adult cancers and ≈ 85% of all primary malignant renal tumors
most commonly in the 5-6th decades; M:F = 2:1Etiology occupational exposures (asbestos, solvents, cadmium),
chromosomal aberrations, tumor suppressor genes cigarette smoking (2×)
RENAL TUMORSRENAL TUMORS
hereditary forms – von Hippel-Lindau disease (angiomatous cerebellar cyst, angiomatosis of the retina, tumors or cysts of the pancreas, multiple bilateral cysts or adenocarcinomas of both kidneys); hereditary papillary renal carcinoma
acquired cystic disease of the kidneys – hemodialysis (> 30×)Pathology origin – proximal renal tubular epithelium originate in the cortex and tend to grow out into perinephric
tissue no true capsule; may have a pseudocapsule of compressed renal
parenchyma, fibrous tissue and inflammatory cells histologically – mixed adenocarcinoma (clear cells, granular cells
and, occasionally, sarcomatoid cells)
RENAL TUMORSRENAL TUMORS
Pathogenesis direct invasion perinephric fat and adjacent visceral structures direct extension renal vein, IVC distant metastases – lung, liver, bone (osteolytic), ipsilateral
adjacent lymph nodes, adrenal gland, brain, the opposite kidney, subcutaneous tissue
Tumor Staging T1 – ≤ 7 cm, limited to the kidney T2 – > 7 cm, limited to the kidney T3 – extends into major veins or directly invades adrenal gland or
perinephric tissues, but not beyond Gerota’s fascia T4 – directly invades beyond Gerota’s fascia
RENAL TUMORSRENAL TUMORS
N1 – single regional lymph node N2 – > 1 regional lymph node M1 – distant metastasisFuhrman Nuclear Grade 1-4 – nuclear size, shape, presence or absence of prominent
nucleoliSymptoms and Signs classical triad (10-15%) – gross hematuria, flank pain, palpable mass gross or microscopic hematuria (60%) dyspnea and cough, seizure and headache or bone pain –
metastatic disease ‘incidentalomas’ !
RENAL TUMORSRENAL TUMORS
Paraneoplastic Syndromes erythrocytosis hypercalcemia hypertension nonmetastatic hepatic dysfunction (Stauffer) - elevation of alkaline
phosphatase and bilirubin, hypoalbuminemia, prolonged prothrombin time and hypergammaglobulinemia
Laboratory Findings – anemia, hematuria, elevated ESRImaging KUB, IVU – calcification overlying the renal shadow, space-
occupying lesion US – renal mass, extension of tumor thrombus into the IVU
RENAL TUMORSRENAL TUMORS
CT – mass that becomes enhanced with the use of i.v. contrast media staging by visualizing the renal hilum, perinephric space, renal vein and vena cava, adrenals, regional lymphatics and adjacent organs
Renal Angiography – nephron-sparing surgery
Radionuclide Imaging – bonescan
MRI (angiography) Positron Emission Tomography
(PET) - detecting recurrence orprogression
Fine-Needle Aspiration
RENAL TUMORSRENAL TUMORS
Differential Diagnosis other solid renal lesions – cysts, angiomyolipomas, renal abscess,
granulomas and arteriovenous malformations, renal lymphoma, transitional cell carcinoma of the renal pelvis, adrenal cancer, metastatic disease
Treatment localized disease open or laparoscopic radical nephrectomy,
open or laparoscopic partial nephrectomy (T1a), ex vivo partial nephrectomy (bench surgery followed by autotransplantation), enucleation of multiple lesions
removal of floating caval thrombi immunological treatment: interferon (α,β,γ), interleukin-2 antiangiogenic agents – Sunitinib, Bevacizumab, Sorafenib,
Temsirolimus
UROTHELIAL TUMORSUROTHELIAL TUMORS
DEPARTMENT OF UROLOGY IAŞI – 2013
BLADDER TUMORSBLADDER TUMORS
2nd most common cancer of the GU tract (1 – prostate) average age at diagnosis – 65 yRisk Factors & Pathogenesis cigarette smoking (2×) α- and β-naphthylamine occupational exposure (chemical, dye, rubber, petroleum,
leather, printing industries) benzidine, β-naphthylamine,4-aminobiphenyl
cyclophosphamide, ? artificial sweeteners physical trauma – infection, instrumentation, calculi activation of oncogenes and inactivation or loss of tumor
suppressor genes (9, 11p21, 17p53) ‘field defect’ of the urothelium
BLADDER TUMORSBLADDER TUMORS
Histopathology epithelial malignancies (98%)
papilloma transitional cell carcinoma (TCC) – 90% – invasion, recurrence &
progression tumor grade – ! carcinoma in situ (CIS) nontransitional cell carcinomas – adenocarcinoma, squamous
cell carcinoma (chronic infection, vesical calculi or chronic catheter use), undifferentiated carcinomas, mixed carcinoma
rare epithelial carcinomas (villous adenomas, carcinoid tumors, carcinosarcomas and melanomas)
rare nonepithelial cancers [pheochromocytomas, lymphomas, choriocarcinomas, mesenchymal tumors (hemangioma, osteogenic sarcoma, myosarcoma)]
BLADDER TUMORSBLADDER TUMORS
direct extension tumours (prostate, cervix, rectum) metastatic tumours (melanoma, lymphoma, stomach, breast, kidney, lung)
Staging – TNM (2002) T – primary tumour
Ta – non-invasive papillary carcinoma Tis – carcinoma in situ T1 – invades subepithelial connective
tissue T2 – invades muscle T3 – invades perivesical tissue T4 – invades prostate, uterus, vagina, pelvic or abdominal
wall
BLADDER TUMORSBLADDER TUMORS
N – lymph nodes N1 – single ≤ 2 cm N2 – single > 2 cm ≤ 5 cm, multiple ≤ 5 cm N3 – > 5 cm
M – distant metastasis M1
Grading – WHO (2004) urothelial papilloma papillary urothelial neoplasms of low malignant potential
(PUNLMP) low-grade papillary urothelial carcinoma high-grade papillary urothelial carcinoma
BLADDER TUMORSBLADDER TUMORS
Symptoms hematuria (85-90%) irritative voiding symptoms – frequency, urgency, dysuria (! CIS) bone pain (metastases), flank pain (retroperitoneal metastases or
ureteral obstruction) – advanced diseaseSigns bimanual examination under anesthesia – bladder wall thickening
or palpable mass (large-volume or invasive tumors) hepatomegaly, supraclavicular lymphadenopathy (metastatic) lymphedema – occlusive pelvic lymphadenopathyLaboratory Findings hematuria, pyuria, azotemia, anemia urinary cytology
BLADDER TUMORSBLADDER TUMORS
Imaging (evaluate the upper urinary tract, assess the depth of muscle wall infiltration and the presence of metastases)
IVU – pedunculated, radiolucent filling defects; fixation or flattening of the bladder wall; UHN
CT & MRI – evaluate extent of bladder wall invasion and detect enlarged pelvic lymph nodes
chest x-ray and radionuclide bone scanCystourethroscopy and Tumor Resection –
diagnosis and initial staging (+ bimanual examination & random bladder biopsies)
BLADDER TUMORSBLADDER TUMORS
Natural History (2 processes) tumor recurrence tumor progression (+ metastasis)Selection of Treatment – based on tumor stage (TNM), grade, size,
multiplicity and recurrence pattern superficial bladder cancer TUR ± intravesical chemotherapy or
immunotherapy low-grade, small tumors TUR + surveillance high-grade, multiple, large, recurrent tumors or associated
with CIS TUR + intravesical chemotherapy or immunotherapy
recurrence of T1G3, after intravesical therapy radical cystectomy
BLADDER TUMORSBLADDER TUMORS
invasive localized tumors (T2, T3) radical cystectomy / irradiation or surgery and systemic chemotherapy
unresectable local tumors (T4) systemic chemotherapy, followed by surgery or irradiation
regional or distant metastases systemic chemotherapy followed by irradiation or surgery
Treatment intravesical chemotherapy (prophylactic or therapeutic) – weekly
for 6 weeks Mitomycin C, Thiotepa, Doxorubicin Bacillus Calmette-Guerin (BCG) - immunotherapy
BLADDER TUMORSBLADDER TUMORS
surgery transurethral resection radical cystectomy partial cystectomy
radiotherapy – external beam irradiation (5000-7000 cGy) chemotherapy – cisplatin, methotrexate, doxorubicin, vinblastine,
cyclophosphamide, 5-fluorouracil; MVAC
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
renal pelvis and ureter rare – 4% of all urothelial cancers bladder : renal pelvis : ureter ≈ 51:3:1 mean age – 65; M:F = 2-4:1 widespread urothelial abnormality – risk
single upper-tract bladder (30-50%) and contralateral upper-tract (2-4%)
bladder low risk (< 2%) of upper tract smoking and exposure to industrial dyes or solvents excessive analgesic intake Balkan nephropathy – interstitial inflammatory disease
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
Pathology transitional cell carcinomas (90-97%) rare – papillomas, squamous carcinomas, adenocarcinomas, mesodermal
tumors (fibroepithelial polyps, leiomyomas, angiomas, leiomyosarcomas) metastatic sites – regional lymph nodes, bone, lung direct extension – renal, ovarian, cervical carcinomas metastatic tumors – stomach, prostate, kidney, breast, lymphomasStaging – TNM (2002) Ta – noninvasive papillary carcinoma; Tis – carcinoma in situ; T1 –
invades subepithelial connective tissue; T2 – invades muscularis; T3 – (renal pelvis) invades beyond muscularis into peripelvic fat or renal parenchyma; (ureter) invades beyond muscularis into periureteric fat; T4 – invades adjacent organs or through the kidney into perinephric fat
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
N1 – single ≤ 2 cm; N2 – single > 2 cm ≤ 5 cm, multiple ≤ 5 cm; N3 – > 5 cm
M1 – distant metastasisGrading – G1 – well differentiated; G2 – moderately differentiated;
G3-4 – poorly differentiated/undiferentiatedSymptoms and Signs gross hematuria (70-90%) flank pain (ureteral obstruction – blood clots, tumor fragments,
tumor itself or regional invasion) anorexia, weight loss, lethargy – metastatic disease flank mass – hydronephrosis or large tumor supraclavicular or inguinal adenopathy or hepatomegaly –
metastatic disease
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
Laboratory Findings hematuria, liver function levels, pyuria, bacteriuria urine cytology (urinary sediment, ureteral catheter, barbotage,
ureteral brush)Imaging IVU – intraluminal filling defect, unilateral
nonvisualization of the collecting system,hydronephrosis ( nonopaque calculi, bloodclots, papillary necrosis, inflammatory lesions)
retrograde uretero-pyelography – dilationof the ureter distal to the lesion (‘goblet’,Bergman's sign) nonopaque ureteralcalculi – narrowing of the ureter distal tothe calculus
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
US, CT, MRI - soft-tissue abnormalities of the renal pelvis, ureterohydronephrosis, regional (lymph node) or distant metastases
Ureteropyeloscopy – retrograde rigid and flexible, ? antegrade (percutaneous); surveillance following conservative surgery
Treatment standard therapy – nephroureterectomy (+ small cuff of bladder)
– open or laparoscopic tumors of the distal ureter – distal ureterectomy and ureteral
reimplantation into the bladder
UPPER UROTHELIAL UPPER UROTHELIAL TUMORSTUMORS
conservative surgery (renal-sparing) – open or endoscopic excision
absolute indications: single kidney, bilateral tumors, marginal renal function
relative indications: low-grade noninvasive tumors instillation of BCG or mitomycin C (through single or double-J
ureteral catheters) follow-up – routine endoscopic surveillance
? postoperative irradiation cisplatin-based chemotherapy - metastatic TCC
top related